Sitemap
Clinical Pharmacology & Toxicology
- Formulation
- Routes of Administration
- Bioavailability
- Rate of Absorption
- Number of Compartments for Drug Distribution
- Volume of Distribution (Vd)
- Extent of Protein Binding
- Elimination and Clearance (Cl)
- Elimination Rate Constant (k)
- Rate of Elimination
- Half-Life
- Mean Residence Time
- Area Under the Curve (AUC)
- Introduction to First Order Kinetics
- First Order Kinetics: Amount of Drug in the Body at a Given Time
- First Order Kinetics: Plasma Drug Concentration
- First Order Kinetics: Drug Half-Life and Fraction Remaining
- Calculating a Drug’s Half-Life in a One Compartment Model
- Estimation of the Initial Drug Concentration in the Two Compartment Model
- Zero Order Kinetics
- Accumulation and Steady State
- Loading Dose
- Maintenance Dose and the Dosage Interval
- Therapeutic Index
- Plasma Drug Level Monitoring
- Guidelines of Rowland and Tozer for Planning a Multiple Dose Regimen
- Loading and Maintenance Doses for an Oral Drug
- Dosing Interval for an Oral Drug
- Maximum Steady State Concentration for an Oral Drug
- Minimum Steady State Concentration for an Oral Drug
- Average Steady State Concentration for an Oral Drug
- Amount of Drug in the Body After the Nth Dose of an Oral Drug
- Plasma Drug Concentration for a Bolus Infusion Regimen
- Loading and Maintenance Doses for a Bolus Infusion Regimen
- Dosing Interval for a Bolus Infusion Regimen
- Maximum Steady State Concentration After Bolus Infusions
- Minimum Steady State Concentration After Bolus Infusions
- Average Steady State Concentration After Bolus Infusions
- Plasma Drug Concentration During an Intermittent Infusion
- Maximum Steady State Concentration During an Intermittent Infusion
- Minimum Steady State Concentration During an Intermittent Infusion
- Plasma Drug Concentration During a Continuous Infusion
- Infusion Rate and Steady State Concentration for a Continuous Infusion
- Plasma Drug Concentration After Starting a Continuous Infusion Without a Bolus Dose
- Plasma Drug Concentration After Starting a Continuous Infusion With a Bolus Dose
- Number of Half-Lives Required for a Drug to Reach a Given Plasma Concentration During a Continuous Infusion Following a Bolus Dose
- Calculating the Estimated Drug Clearance and Maintenance Dose in Renal Insufficiency
- Maintenance Dosage Fraction Based on the Fractional Rate Constant
- Adjusting a Constant Infusion in Renal Insufficiency
- Determining the Maintenance Dose of an Oral Drug Needed to Achieve a Steady State Concentration in a Patient in Renal Failure
- Features of a Drug Likely to Be Removed During Renal Dialysis
- Pregabalin Dose Adjustment for a Patient with Impaired Renal Function
- Adjusting the Dose of Allopurinol for Renal Function
- Estimated Salicylate Serum Levels
- Acetaminophen Serum Levels (Rumach-Matthew Nomogram)
- Ibuprofen Serum Levels in Overdosage
- Monitoring a Patient on Chronic Aspirin Therapy
- Pseudosepsis Syndrome in Salicylate Intoxication
- Clinical Features of Salicylate Intoxication in a Neonate
- When to Suspect Salicylate Intoxication in an Elderly Patient
- Risk Factors of Alander et al for Hepatocellular Injury in a Pediatric Acetaminophen Overdose
- Nomogram of Sivilotti et al for Predicting Hepatotoxicity Following Acetaminophen Poisoning
- Risk Factors for Severe Hepatotoxicity in a Patient with Acetaminophen (Paracetamol) Poisoning
- Treatment Line for a Patient at Increased Risk for Acetaminophen (Paracetamol) Toxicity
- Recommendations of Anderson et al for a Young Child Who Has Taken an Overdose of Acetaminophen Elixir
- Amount of Acetaminophen Consumed Daily By a Person Abusing an Over-the-Counter (OTC) or Prescription Medication
- Calculating the Exposure to Acetaminophen for a Child Given the Concentrated Infant Formula Rather Than the Children's Formula
- Respiratory Depression Associated with Opioid Analgesia
- Sedation Associated with Opioid Analgesia
- Delirium Associated with Opioid Analgesia
- Genitourinary Problems in Men Associated with Opioid Analgesia
- Using Naloxone to Reverse Adverse Effects of an Opioid Analgesic
- Itching (Pruritus) Associated with Opioid Analgesia
- Clinical Findings of Opioid Toxicity in a Patient Being Treated for Pain
- Risk Factors for Opioid Toxicity in a Patient Being Treated for Pain
- Pulmonary Syndromes Complicating Salicylate Therapy
- Calculating Total Daily Dose by Body Weight
- Calculating Total Daily Dose by Height
- Calculating Total Daily Pediatric Dose by Body Surface Area
- Calculating Total Daily Dose by Age
- Age Adjustment for Maintenance Dose
- Calculating Dose Given by Body Weight or BSA
- Determining Drip Rate for Drug Infusion Using Microtubing
- Determining the Infusion Rate of Intravenous Solutions in Drops per Minute
- Preventing Adverse Events Associated with the Use of an Infusion Pump
- Prevention of Tampering with a Narcotic Infusion Pump
- Ethanol Intoxication
- Estimated Blood Ethanol Level from Body Weight and Number of Drinks
- Blood Ethanol Levels and the Diagnosis of Alcohol Abuse
- Urine Ethanol Levels
- Blood Alcohol Estimation from Osmolal Gap
- The AUDIT Clinical Procedure to Evaluate Patients for Harmful Effects of Alcohol Use
- The Alcohol Symptom Checklist of Teplin and Lutz
- Measurement of Breath Alcohol
- Disulfiram-Like Reaction to Alcohol Ingestion (Antabuse Reaction, Acetaldehyde Syndrome
- Equation of Vogel et al for Evaluating Ethanol Intoxication in Children
- Alcohol-Induced Hangover Symptoms of Pittler et al
- Alcohol-Induced Hangover Symptom Survey of Wiese et al
- Criteria of Wiese et al for Alcohol-Induced Hangover
- Predicting the Likelihood of a Hangover Based on the Amount and Type of Alcohol Intake
- Estimation of a Person's Alcohol Intake Over Several Years
- Evaluating a Fatal Ethanol Overdose Using Widmark's Equation and the Ethanol Concentration in Blood and Urine
- Fatal Flaws in an Alcohol Screening Test Performed As a Department of Transportation (DOT) Regulated Test
- Fatal Flaws in an Alcohol Confirmatory Test Performed As a Department of Transportation (DOT) Regulated Test
- Clinical Findings of Alcohol Intoxication in a Young Child
- Horizontal Gaze Nystagmus Sobriety Test of Good and Augsburger
- Walk and Turn Test for Estimating Sobriety
- Combining Results of the Horizontal Gaze Nystagmus and the Walk and Turn Tests
- One Leg Stand Test for Field Sobriety Testing
- Reciting the Alphabet in Field Sobriety Testing
- Finger-to-Nose Test in Field Sobriety Testing
- Ratio of Urinary 5-Hydroxytryptophol to 5-Hydroxyindoleacetic Acid (5-HTOL to 5-HIAA Ratio) to Determine Ethanol Ingestion or Postmortem Ethanol Production
- Findings Suggesting In Vitro Ethanol Production in Blood, Tissue or Urine
- Complications Associated with Ingestion of Pruno (Prison Wine)
- Complications Associated with Ingestion of Moonshine
- Beer or Cider Potomania
- Method of Forrest for Estimating Widmark's Factor in a Patient
- Equation of Wagner et al for Estimating the Amount of Alcohol Ingested from a Single Blood Alcohol Concentration
- Risk Factors for Lead or Iron Poisoning Associated with Homemade Alcohol (Including Sapa of Ancient Rome)
- Handling of a Patient with "Shy Lung" During Alcohol Breath Testing
- Adverse Effects Associated with Ingesting a "Substitute" Alcohol
- Specimen Collection for Urine Drug Testing
- Substance Abuse and Mental Health Services Administration (SAMHSA) Definitions for Validity of a Urine Specimen
- Urine Excretion of Benzoylecgonine Following Cocaine Use
- Identification of Heroin Use With Hair Analysis
- Duration of Detectability of Drugs of Abuse in the Urine
- 6-Acetylmorphine and the Ratio of Morphine to Codeine in the Evaluation of a Patient for Heroin Use
- Significance of a Negative Urine Drug Screen for Opiates in a Person with a Prescription for Narcotic Analgesics
- Evaluation of Urinary Opiate Levels After Ingestion of a Poppy Seed Product
- Handling the Patient Unable to Provide Sufficient Urine for Testing (Shy Bladder Syndrome)
- Requirements for a Collector of Urine Specimens Submitted for DOT Drug Testing
- Fatal Flaws in Urine Drug Testing
- Criteria for Refusal to Take a Department of Transportation (DOT) Drug Test
- Indications for a Directly Observed Urine Specimen Collection for Drug Testing
- Reporting the Results of a Urine Drug Test
- Performing a Physical Examination on a Donor with a Positive Test for Opiates
- When to Consider Collection of an Alternative Specimen for Drug Testing
- Findings on Urine Drug Testing in a Patient Using a Vicks Vapor Inhaler
- Criteria for Reasonable Suspicion of an Employee Being Under the Influence of Drugs or Alcohol
- Evaluation of an Employee with a Positive Urine Test for Marijuana Who Claims Hemp Food Consumption
- Correctable Flaws in Drug and Alcohol Testing
- When to Redesignate the Specimen Bottles of a Split Specimen Collection
- Identification of the Donor for a Drug or Alcohol Test
- Situations When a Medical Review Officer (MRO) May Change a Verified Result
- Actions by the Medical Review Officer (MRO) That Are Prohibited During a Drug Test Result Verification
- Review of Negative Drug Test Results by the Medical Review Officer (MRO)
- Validity Tests to Perform on Oral Fluid Used in Testing for Drugs of Abuse
- Validity Tests to Perform on Sweat Used in Testing for Drugs of Abuse
- Validity Tests to Perform on Hair Used in Testing for Drugs of Abuse
- Legal Problems That May Arise When Testing for Drugs of Abuse
- Reporting Results of a Double Specimen Collection During a Single Testing Event (Immediate Directly Observed Collection)
- Evaluation of a Patient for Concurrent Use of Cocaine and Alcohol Including Measurement of Cocaethylene
- Submission of Blind Quality Control Samples by an Employer to a Drug Testing Laboratory
- World Anti-Doping Agency (WADA) Formula for Normalizing a Urine Drug Concentration Based on the Specific Gravity
- Determining the Minimum Number of Safety-Sensitive Workers Who Need To Be Randomly Tested To Meet the Department of Transportation (DOT) Requirements
- Selecting a Worker or Donor at Random to Screen for Drugs of Abuse, Method 1
- Urine Marijuana Metabolite to Creatinine Ratio of Huestis and Cone for Identifying New Use
- False Positive Adulterant Tests for pH or Nitrite Associated with a Urinary Tract Infection
- False Positive Immunoassay for Tetrahydrocannabinol (THC) in a Patient Being Treated with Pantoprazole or Other Proton Pump Inhibitor
- Measuring Drugs of Abuse in Finger or Toe Nails
- Selecting a Worker or Donor at Random to Screen for Drugs of Abuse, Method 2
- Detecting Urinary 11-nor-delta9-tetrahydrocannabivarin-9-carboxylic Acid to Identify Marijuana Use in a Patient Taking Marinol
- Why to Identify the Specific Opiate Causing a Positive Urine Drug Test
- Causes of a False Positive Screening Urine Drug Test
- Causes of a Negative Screening Urine Drug Test
- Positive Urine Screening Test for Benzodiazepine or THC in an HIV-Positive Patient Taking Efavirenz
- Unexplained Methamphetamine and Amphetamine in a Sample Due to Benzamphetamine (Didrex), Famprofazone or Other "Precursor" Drug
- Adjusting a Urine Drug or Chemical Level in Urine for the Specific Gravity of the Sample
- In Vitro Formation or Degradation of 6-Acetyl Morphine (6-AM)
- Testing for EDDP in a Patient Receiving Methadone
- Opioid Process Impurities in the Manufacture of an Opioid Analgesic
- Ratio of Urine Concentrations of Hydromorphone to Morphine
- False Positive Opiate Immunoassay Associated with Naloxone
- Non-Negative Test Results
- Collection of Hair for Drug Testing
- Indications to Perform a Complete Analysis of a Drug of Abuse
- The Clinical Institute Withdrawal Assessment (CIWA-A) for Patients in Alcohol Withdrawal
- The Benzodiazepine Withdrawal Scale (CIWA-B)
- Subjective Scoring Index for Opiate Withdrawal during Naloxone Therapy
- Neonatal Drug Withdrawal Scoring System of Lipsitz
- Scoring System of Finnegan et al for the Neonatal Abstinence Syndrome
- Neonatal Withdrawal Inventory
- Self-Rating Scale for Barbiturate-Benzodiazepine Withdrawal
- The Moro Scale Score in Neonatal Narcotic Withdrawal
- The Amphetamine Withdrawal Questionnaire (AWQ)
- The Clinical Institute Narcotic Assessment (CINA) Scale for Withdrawal Symptoms
- Grades of Fultz and Senay for Opiate Withdrawal
- Grading Delirium Tremens (DTs) During Ethanol Withdrawal
- Indications of Fiellin et al for Detoxification of an Alcoholic as an Inpatient
- Clinical Findings of Tenenbein et al for Neonatal Withdrawal Associated with Maternal Volatile Substance Abuse
- Indications of Ritson for Referral of an Alcoholic for Detoxification (Inpatient or Other Specialized Service)
- Clinical Findings of Sanz et al for Neonatal Withdrawal Associated with Maternal Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
- Clinical Signs of Methcathinone Withdrawal
- Neonatal Withdrawal Symptoms Following Maternal Phencyclidine (PCP) Abuse During Pregnancy
- Clinical Signs of Caffeine Withdrawal
- Clinical Signs of Dyer et al for Gamma-Hydroxybutyric Acid (GHB) Withdrawal
- Clinical Findings of Withdrawal from Anabolic Steroids
- Risk Factors of Lukan et al for Delirium Tremens Developing in an Intoxicated Trauma Patient
- Clinical Features of Haney et al for Marijuana Withdrawal
- Clinical Features of Paraldehyde Withdrawal
- Clinical Features of Meprobamate or Carisoprodol Withdrawal Syndrome
- Clinical Features of Gabapentin Withdrawal Syndrome
- Symptoms Score of Judson et al for Opioid Dependence Following Parenteral Administration of Naloxone
- Sophia Observation withdrawal Symptom scale (SOS) for Opioid or Benzodiazepine Withdrawal in a Pediatric Patient
- Scopolamine Withdrawal
- Monoamine Oxidase Inhibitor (MAOI) Withdrawal
- Antipsychotic Medication (Neuroleptic) Discontinuation Syndrome
- Withdrawal Syndrome Associated with Discontinuation of Intrathecal Baclofen Therapy
- Placental Score of Domenici et al for Identifying a Neonate at Risk for Severe Withdrawal Reaction
- Screening a Trauma Patient for Risk of Delirium Tremens Using the AST and MCV
- Adverse Effects of Abrupt Beta-Blocker Withdrawal
- Discontinuation or Post-Removal Symptoms of Scopolamine or Other Antimuscarinic Agents
- Ruxolitinib Withdrawal Syndrome (Ruxolitinib Discontinuation Syndrome)
- Grading Depressant Drug Coma
- Accumulative Prognostic Index in Patients with Depressant Intoxication
- Intoxication Score in Short Acting Barbiturate Overdosage
- Clinical Prediction Rule of Christenson et al for Early Discharge of Patients After Presumed Opioid Overdosage
- EEG Changes of Haider et al in Sedative Overdosage and Coma
- Risk Factors for Death Following Initiation of Methadone Maintenance Therapy
- Clinical Findings in Phencyclidine (PCP) Intoxication
- Clinical Findings in Methcathinone Intoxication
- Clinical Findings in Gamma-Hydroxybutyric Acid (GHB) Intoxication
- Clinical Findings in Dextromethorphan Intoxication
- Clinical Findings in LSD (d-Lysergic Acid Diethylamide) Intoxication
- Clinical Findings in an Intoxication with a Piperazine Derivative (Benzylpiperazine or Trifluoromethylphenylpiperazine)
- Clinical Findings in an Intoxication with 4-Bromo-2,5-DMPEA (4-Bromo-2,5-Dimethoxyphenethylamine)
- Clinical Findings in Ketamine Intoxication
- Clinical Findings in MDMA (3,4-Methylenedioxymethamphetamine, Ecstasy) Intoxication
- Clinical Findings in Flunitrazepam (Rohypnol) Intoxication
- Clinical Findings in 4-Methylthioamphetamine (4-MTA) Intoxication
- Clinical Findings in Methamphetamine Intoxication
- Clinical Findings in Cocaine Intoxication
- Clinical Findings of Cocaine or Amphetamine Abuse in a Pregnant Woman
- Risk Factors for an Accidental Heroin Overdose
- Recommendations of Desai et al for Handling a Patient Who Is Addicted to an Over-the-Counter (OTC) Medication
- Clinical Features of a Caffeine Overdose
- Clinical Findings in Marijuana Intoxication
- Cocaine "Washed-Out" Syndrome
- Risk Factors for Seizures in a Person Who Abuses Cocaine
- Causes of Abdominal Pain and Peritonitis in a Person Who Abuses Cocaine
- Ginseng Abuse Syndrome
- Complications of Roszler et al for Intravenous Drug Injections Into the Groin
- Clinical Features of Paraldehyde Abuse
- Clinical Features of Chloral Hydrate
- Heavy Metal Poisoning Associated with an Improperly Made Drug of Abuse
- Grading the Severity of Intoxication with a CNS Stimulant
- Ocular Changes in Drug Misuse
- Clinical Findings in a Patient Abusing Nonpharmaceutical Fentanyl (NPF)
- Clinical Findings in Intoxication with a Tryptamine
- Hazards of Other Medications Ingested During the Abuse of an Over-the-Counter (OTC) Medication
- Parkinsonism from Exposure to MPTP Contaminating a Synthetic Meperidine Analogue
- Noncardiogenic Pulmonary Edema (NCPE) Associated with a Heroin or Opiate Overdose
- Control of Chronic Skin Ulcerations Secondary to Injections of Abused Drugs
- Urinary Tract Changes Associated with Ketamine Abuse in Hong Kong
- Status Asthmaticus Triggered By Heroin Inhalation
- Transient Ischemic Colitis Following Use of Amphetamine or Cocaine
- Clinical Findings in Gamma-Butyrolactone (GBL) or 1,4-Butanediol (1,4-BD) Intoxication
- Excited Delirium Associated with Cocaine Intoxication
- Signs and Symptoms of Buprenorphine Misuse
- Flumazenil Therapy for Reversal of Benzodiazepine Effects
- Signs and Symptoms of Carisoprodol Misuse
- Synthetic Cannabinoids (Spice Drugs, K2, JWH-018, JWH-073, CP 47497, HU-210)
- Clinical Features of Mephedrone Intoxication (Bath Salts)
- Cannabis Hyperemesis Syndrome (CHS)
- Pulmonary Talcosis Following Intravenous Abuse of an Oral Medication
- Toxic Leukoencephalopathy Following Heroin Smoking (Heroin Vapor Abuse, "Chasing the Dragon")
- Differential Diagnosis of Dyspnea in a Person Who Abuses Drugs
- Hyponatremia Associated with MDMA (Ecstasy) Intoxication
- Spectrum of Acute Renal Injury Associated with MDMA (Ecstasy) or Other Party Drugs
- Importance of a Complete Medical Examination in a Patient with a Suspected Drug Overdose
- "Parachuting" an Oral Drug of Abuse
- Respiratory Depression Due to Co-Ingestion of Two or More CNS Depressants (Ethanol and Benzodiazepines, Opiates and Muscle Relaxants, Other)
- Pneumomediastinum and Cervical Soft Tissue Emphysema Associated with Drug Abuse
- Ways That a Fentanyl Transdermal Patch May Be Abused
- Monitoring Drugs Using the Concentration in Saliva
- When to Measure a Drug Metabolite
- Risk of Noncompliance in Use of Medications
- The Pill Identification Test for Assessing Compliance with Therapy
- Self-Reported Medication Adherence Scale of Morisky et al
- Adherence Score of Duong et al for Patients on Antiretroviral Therapy
- Simplified Medication Adherence Questionnaire (SMAQ)
- Modified Questionnaire of Duong et al to Identify Reasons for Missing Medication Doses
- Method of Ho et al for Grading Adherence to Antiretroviral Therapy
- Rating of Medication Influences (ROMI) Scale of Weiden et al for Compliance with Drug Therapy in Schizophrenia
- Method of Kent et al for Improving Adherence in HIV-Infected Patients
- Overcompliance with a Medication
- Reasons Listed by Fuhrer et al for Noncompliance by Patients with Pressure Ulcers
- Findings Suggesting Noncompliance in the Use of Medications
- Factors Identified by George et al Affecting Adherence in a Patient with Chronic Obstructive Pulmonary Disease (COPD)
- Directly Observed Therapy (DOT)
- Enablers and Incentives in a Patient-Centered Treatment Strategy to Increase Patient Compliance with a Long-Term Therapeutic Regimen
- Risk Factors for Noncompliance in Thienopyridine Therapy by a Cardiac Patient with a Drug-Eluting Stent
- Factors of Walker et al Affecting Adherence to Medications for Prevention of Type 2 Diabetes
- Factors of Moynihan et al Affecting the Adherence of a Male with Testicular Cancer to Medical Advice
- Model of Chisholm-Burns et al for Predicting the Adherence Rate of a Renal Transplant Recipient to Immunosuppressant Therapy
- Risk Factors of D'Inca et al for Nonadherence to Drug Therapy in a Patient with Inflammatory Bowel Disease (IBD)
- Risk Factors of Copp et al for Compliance with Antibiotic Prophylaxis for Vesicoureteral Reflux
- Predictors of Shah et al for a Patient Filling the First Prescription ("First-Fill") for an Antihypertensive Medication
- Predictors of Solomon et al for a Woman with Osteoporosis Showing Low Adherence to Bone Protective Medications
- Factors of Zaghloul et al Affecting Compliance with Therapy for Psoriasis
- Factors of Myat et al Affecting Compliance with Antihypertensive Therapy
- Factors Affecting Adherence with Iron Chelation Therapy (ICT)
- Multicentre Study of Poisoning in Children (MSPC) Score
- Poisoning Severity Score in Acute Poisoning
- Estimating the Amount of Agents Ingested in an Acute Poisoning
- Modified Oklahoma Poisoning Questionnaire (OPQ) for Predicting Recurrent Accidental Poisoning in a Young Child
- Indications for Digoxin Blood Level Monitoring
- Reversing Digoxin Overdosage with Fab Antibody Fragments
- Algorithm of Salhanick and Shannon for Management of Acute Poisoning with a Calcium Channel Antagonist
- Cinchomism Associated with Quinidine or Quinine Therapy
- Risk Factors for Digitalis Toxicity
- Risk Factors for Calcium Channel Blocking Agent Toxicity
- Clinical Findings with a Beta-Blocker Intoxication
- Monitoring of N-Acetylprocainamide (NAPA) in a Patient Being Treated with Procainamide
- Equation of Nicholson et al for Prescribing Digoxin
- Simple Score of Nicholson et al for Prescribing Digoxin
- Clinical Findings Suggesting the Possibility of a Surreptitiously Administered Sedative
- Steps to Avoid Surreptitious Sedative Ingestion ("Being Slipped a Mickey")
- Hangover Symptoms Following the Use of a Benzodiazepine as a Hypnotic Drug
- Risk Factors for Hangover Symptoms Following the Use of a Benzodiazepine as a Hypnotic Drug
- Evaluation of a Worker with a Post-Accident Drug Test Showing the Presence of a Benzodiazepine
- Failure to Recall an Activity After Use of a Soporific Benzodiazepine (Temazepam, Triazolam)
- Score of Naranjo et al for Estimating the Probability of an Adverse Drug Reaction in a Patient
- French System for Monitoring Unexpected or Toxic Drug Reactions (UTDR)
- Identifying Elderly Patients with Risk Factors for Adverse Drug Reactions
- Risk Factors of Field et al Associated with Adverse Drug Reactions in Nursing Home Residents
- Algorithm Used by the FDA Division of Drug Experience to Evaluate the Causal Relationship in an Adverse Drug Reaction
- Managing Common Adverse Reactions to alpha-Interferon
- Findings of Trontell Suggestive of a Possible Adverse Drug Reaction
- Risk Model of McElnay et al for Adverse Drug Events in an Elderly Patient
- Modified Criteria of Schumrock and Thornton for Preventability of an Adverse Drug Reaction (ADR)
- Classification of McDonnell and Jacobs for the Severity of an Adverse Drug Reaction
- Comorbid Conditions Contributing to Repeat Hospital Admissions for an Adverse Drug Reaction (ADR) in Older Adults
- Risk Factors of Green et al for Adverse Drug Events in an Elderly Outpatient
- GerontoNet ADR Risk Score of Onder et al for Determining Risk of Adverse Drug Reactions in a Hospitalized Geriatric Patient
- WHO Adverse Reaction Terminology (WHO-ART) Classification for Adverse Drug Reactions
- Seven Deadly Sins of Inman for Reporting Adverse Drug Reactions (ADR)
- Kinetic Features of a Poison Making Removal Amenable to an Extracorporeal Technique
- Indications for Extracorporeal Elimination of Salicylate
- Indications and Contraindications for Whole Bowel Irrigation (WBI)
- Toxic Agents with Poor Adsorption Onto Activated Charcoal
- Gastric Lavage
- Problems Associated With the Use of Ipecac to Induce Emesis
- Use of Cathartics to Aid in Gut Decontamination
- Accidental Injection or Extravasation of Vasoconstricting Drugs into Subcutaneous Tissues
- Reducing the Risk of Improper Intrathecal Drug Injection
- Risk of Extravasation Injury Associated with an Intravascular Infusion in a Peripheral Vein
- Risk for Chemical Mediastinitis Associated with Extravasation of Drug from a Central Intravascular Catheter
- Grading the Severity of Infiltration and Extravasation Injury
- Clinical Features of an Allergic Flare Reaction to Intravenous Infusion of a Drug
- Preventing Complications Associated with Intramuscular (IM) Injections
- Techniques of Gault for Prevention of Extravasation Injury
- Criteria of Spenny et al for the Compartment Syndrome Following Extravasation Injury
- Changes in Subcutaneous Fat at Sites of Insulin Injection (Lipoatrophy or Lipohypertrophy)
- Complications Associated with Intramuscular Injections
- Risk Factors for Subcutaneous Abscess or Cellulitis Associated with Continuous Insulin Infusion with an Insulin Pump
- Cosmetic Skin Changes at the Site of Repeated Subcutaneous Injections
- Risk Factors for Unintentional Intra-Arterial Drug Injection
- Clinical Findings Following Unintentional Intra-Arterial Drug Injection
- Indicators for Identifying an Unintentional Intra-Arterial Drug Infusion
- Factors of Chan et al That Determine Whether an Intramuscular Injection into the Buttocks Reaches Muscle or Fat
- Recommendations of Grissinger for Reducing the Risk of Serious Complications Associated with Intravascular Injection of a Caustic Drug
- Traumatic Neuritis of the Sciatic Nerve Following Intramuscular (IM) Injection
- Local Injection Site Reaction to Subcutaneous Administration of Etanercept
- Nicolau's Syndrome (Embolia Cutis Medicamentosa)
- Hoigne Syndrome (Pseudo-anaphylaxis, Procaine Psychosis) Following Injection of Procaine Penicillin or Other Drugs
- Aluminium Granulomata (Aluminum Granulomata) at an Injection Site
- Central Nervous System Oxygen Toxicity
- Pulmonary Oxygen Toxicity
- Clinical Features of the Anticholinergic and Central Anticholinergic Syndromes
- Screening for Anticholinergic Drug Toxicity Using Intravenous Physostigmine
- Anticholinergic Risk Scale of Rudolph et al
- Muscarinic Effects of a Cholinergic Agent
- Nicotinic Effects of a Cholinergic Agent
- Criteria for Chelation Therapy in Patients with Iron Intoxication
- Determining the Amount of Elemental Iron Ingested
- Clinical Stages of Iron Intoxication
- Criteria for Hepatotoxicity Associated with Acute Iron Poisoning
- Criterion of Yatscoff et al for Discontinuation of Desferoxamine Therapy for Acute Iron Poisoning
- Desensitization to Asparaginase
- Clinical Features of the Anticonvulsant (Antiepileptic) Drug Hypersensitivity Syndrome
- Risk Factors Associated with the Anticonvulsant (Antiepileptic) Drug Hypersensitivity Syndrome
- Questions of Lorenz et al for Determining If a Drug Has Caused a Release of Histamine
- Criteria of Lorenz et al for Histamine Release Response Associated with a Drug
- Classification of Lorenz et al for the Severity of a Drug-Induced Histamine Release Response
- Recognition of an Allergic Reaction to an Antiretroviral Medication
- Aspirin Triad Syndrome
- Hypersensitivity Reaction to Paclitaxel (Taxol)
- Hypersensitivity Reaction to Drugs Formulated with Cremophor EL (Polyethoxylated Castor Oil)
- Hypersensitivity Reactions to Tartrazine (FD&C Yellow No. 5)
- Risk Factors of Schindewolf et al for a Delayed Hypersensitivity Type Skin Reaction to Heparin
- Anaphylactic Response Following Injection of a Corticosteroid
- Hypersensitivity Reaction to Clopidogrel
- Risk Factors for a Patient with an Allergy to a Sulfonamide Antibiotic Reacting to a Sulfonamide Nonantibiotic
- Allergic Reactions to the Coloring Agent E110 (Sunset Yellow FCF)
- Estimating the Plasma Level of Propylene Glycol from Osmolal Gap
- Evaluating a Patient for Possible Propylene Glycol Toxicity
- Adverse Effects of Benzyl Alcohol, Including the Gasping Syndrome in Premature Infants
- Clinical Features of Acute Camphor Intoxication
- Cardiotoxicity and Neurotoxicity Following Infusion of 5-Fluorouracil Prepared in Tris Buffer
- Determining the Isoniazid Acetylation Phenotype Based on Measurement of Urinary Isoniazid and Acetylisoniazid
- Thiopurine Methyltransferase (TPMT) Activity and Azathioprine Therapy
- Effect of Polymorphism in Cytochrome P450 (CYP) CYP2D6 on the Metabolism of Oxycodone
- Indications for Testing a Patient on Warfarin for Polymorphism in Cytochrome P450 (CYP) CYP2C9
- Identifying a Patient Failing Therapy for Helicobacter pylori Who Should be Phenotyped for CYP2C19
- Model of Steimer et al for Predicting Adverse Side Effects During Amitriptyline Therapy Based on the CYP2D6 and CYP2C19 Phenotypes
- Generic Model for Pharmacologic Effects of a Drug Undergoing Metabolism to an Active Compound
- Identifying Patients at Risk for Irinotecan (Camptosar) Myelotoxicity Based on UGT1A1 Genotype (Including Gilbert's Syndrome)
- Voriconazole Serum Concentration and CYP2C19 Genotype
- Methotrexate Toxicity and MTHFR (Methelenetetrahydrofolate Reductase) C677T Polymorphism
- Identifying a Woman at Risk for Reduced Effectiveness of Tamoxifen Therapy Secondary to Altered Biotransformation
- Pharmacogenetic Model of Wessels et al for Predicting the Efficacy of Methotrexate Monotherapy at 6 Months in a Patient with Rheumatoid Arthritis
- Efavirenz Dose Reduction in an HIV-1 Infected Patient Based on CYP2B6 Genotype
- Nomogram of Schwab et al for Predicting Severe Toxicity Associated with Fluorouracil (5-FU) Therapy
- HLA Screening to Identify an Asian Patient at Risk for Carbamazepine-Associated Stevens-Johnson Syndrome
- Impact of CYP2C19 Phenotype on Clopidogrel Response
- Apoptotic Pharmacogenetic Index (API) of Hlavaty et al for Infliximab Therapy in Crohn's Disease
- Testing a Patient for Polymorphism in the ABCB1 Gene Prior to Therapy with Docetaxel or Irinotecan
- Risk Factors of Park et al for Severe Hyperbilirubinemia in an HIV-Positive Patient Receiving Atazanavir
- Effect of Polymorphism in Cytidine Deaminase on the Pharmacokinetics of Gemcitabine
- Common Drugs Inducing or Inhibiting Cytochrome P450 Enzymes and the P-Glycoprotein Transporter System
- Interference By Grapefruit, Cranberry and Other Juices With Drug Metabolism
- Ratio of Urinary 6-Beta-Hydroxycortisol to Cortisol to Phenotype CYP3A4 Activity
- Findings Suggestive of a Change in Drug Metabolism (Induction or Inhibition)
- Differential Diagnosis of Medication Intolerance
- Criteria of Pinilla-Ilbarz et al for Drug Intolerance
- Indications for Antiepileptic Drug Monitoring
- Clinical Features of a Carbamazepine Overdose
- Equation of Umstead and Neumann for Predicting Free Phenytoin Based on the Serum Albumin in a Cancer Patient
- The Sheiner-Tozer Equation for Normalizing the Total Serum Phenytoin Concentration in a Patient with Hypoalbuminemia
- Normalizing the Total Serum Phenytoin Concentration for a Patient with End Stage Renal Disease and Hypoalbuminemia
- Estimate of Dasgupta et al for Free Phenytoin Concentration
- Estimating the Volume of Distribution for Phenytoin in a Patient with Hypoalbuminemia
- Indications for Direct Measurement of the Free (Unbound) Serum Phenytoin Concentration
- Equation of Coleman et al for Calculating the Free Phenytoin Concentration at 37°C Based on Testing at Room Temperature
- Model of Allison et al for Estimating Carbamazepine 10,11- Epoxide Concentration in Serum Based on Carbamazepine Levels by 2 Different Immunoassays
- Equation of May et al for Predicting Unbound Concentration of Phenytoin in a Patient Being Treated with Phenytoin and Valproic Acid
- Equation of Haidukewych et al for Predicting Unbound Concentration of Phenytoin in a Patient Being Treated with Phenytoin and Valproic Acid
- Clinical Findings in a Patient with an Overdose of Valproic Acid
- Administration of L-Carnitine in a Patient with an Overdose of Valproic Acid
- Risk Factors for Toxicity Associated with Infusions of Sodium Nitroprusside
- Clinical Findings Suggestive of Cyanide Poisoning
- Exposures That May Be Associated with Cyanide Poisoning
- Arteriolization of Venous Blood in Cyanide Poisoning
- Clinical Features of a Patient Who Abuses Volatile Solvents
- Techniques Used to Abuse Volatile Inhalants
- Complications Associated With Volatile Inhalant Abuse
- Signs and Symptoms of Withdrawal in a Person Who Abuses a Volatile Inhalant
- Method of Wong et al for Abbreviated Monitoring of Tacrolimus in a Renal Transplant Recipient
- Method of Weber et al for Abbreviated Monitoring of Mycophenolic Acid (MPA) in a Pediatric Renal Transplant Recipient Receiving Mycophenolate Mofetil (MMF)
- Method of Filler and Mai for Abbreviated Monitoring of Mycophenolic Acid (MPA) in a Pediatric Renal Transplant Recipient Receiving Mycophenolate Mofetil (MMF)
- Contraindications to Intravenous Colchicine Administered to a Patient and Indications to Reduce the Dose Administered
- Clinical Stages of Colchicine Toxicity
- Ways That a Patient May Develop Colchicine Intoxication
- Clinical Finding in Isoniazid (INH) Overdosage
- Administration of Pyridoxine (Vitamin B6) as the Antidote to Isoniazid Intoxication
- Management of a Patient with an Acute Isoniazid Overdose
- Risk Factors for Isoniazid Hepatotoxicity
- Monitoring a Patient for Evidence of Isoniazid Hepatotoxicity
- Clinical Features of an Overdose with Diphenhydramine or Other H1-Receptor Antagonist
- Paradoxical Excitation Associated with Diphenhydramine (Benadryl)
- Sedative Effects of Antihistamine Drugs
- Signs and Symptoms of Toxicity Associated with Doxylamine Succinate
- Risk Factors for Theophylline Intoxication
- Clinical and Laboratory Findings in Theophylline Intoxication
- Indications of Dawson et al for Admitting a Patient to the Hospital with Theophylline Intoxication
- Indications of Williams and Erickson for Hemodialysis or Hemoperfusion in a Patient with Theophylline Intoxication
- Clinical Findings in a Patient Receiving an Overdose of Methylene Blue
- Serotonin Syndrome Associated with Methylene Blue Therapy
- Adverse Effects Associated with the Antitussive Agent Benzonatate
- Inhibition of Organic Anion Transporting Peptide 1A2 (OATP1A2) By Grapefruit and Other Fruit Juices
- Drugs Associated with Drug-Induced Phospholipidosis (DIP)
- Diagnostic Features of Drug-Induced Phospholipidosis (DIP)
- Hepatic Phospholipidosis
- Impact on Drug Delivery of Placing an Infusing Central Catheter Too Close to a Central Catheter Being Used for Blood Removal
- Drugs Associated with a False Positive Screen for Phencyclidine (PCP)
- Withdrawal Syndrome Associated with Discontinuation of Dextromethorphan Abuse
- Zolpidem Withdrawal Syndrome
- Toxic Effects of Propoxyphene (Dextropropoxyphene, Darvon, Darvocet)
- Early Discontinuation of Therapy
- Predictors of Owusu et al for Tamoxifen Discontinuation in an Older Woman with Estrogen-Receptor Positive Breast Cancer
- Classification of Tsai et al for the Severity of an Acute Poisoning
- Score of Du et al for Detecting an Adverse Drug Reaction (ADR) in the Neonatal Intensive Care Unit
- Risk Factors of Rashed et al for Adverse Drug Reactions in a Hospitalised Child
- Risk Factors of Kane-Gill et al for Adverse Drug Events (ADE) in a Critically-Ill Patient
- Adverse Drug Event (ADE) Trigger Tool: Clinical Events
- Adverse Drug Event (ADE) Trigger Tool: Administration of an Antidote
- Adverse Drug Event (ADE) Trigger Tool: Laboratory Tests
- Unsafe Injection Practices
- Indications for Chelation Therapy for a Transfusion-Dependent Patient with Myelodysplasia and Iron Overload
- Phenotypes of Cytochrome P450 2D6
- Risk Factors of Pawasauskas et al for Naloxone Use to Reverse Oversedation or Respiratory Depression in a Hospitalized Patient
- Impact of Variation in the Aldehyde Dehydrogenase (ALDH2) Gene and Alcohol Use in Japanese and Other Asians
- Estrogenic Effects Associated with Phytoestrogens in Alcoholic Beverages
- Congeners in Alcoholic Beverages
- Alcohol-Induced Pain
- Acute Alcohol Poisoning
- Auto-Brewery Syndrome (Colonic Fermentation with Endogenous Ethanol Production)
- Quetiapine Discontinuation Syndrome
- Synthetic Cannabinoid Withdrawal Syndrome
- Risk Factors for Quetiapine Abuse
- Rachacha Ingestion
- Treatment Fatigue
- Adverse Drug Reactions Associated with Breastfeeding
- Risk Factors of Pedros et al for Being Hospitalized for an Adverse Drug Reaction
- Clinical Prediction Rule of Sakuma et al for Adverse Drug Events in a Hospitalized Adult Patient
- Score of Urbina et al for a Drug-Related Problem in a Hospitalized Patient
- Use of 1% Lidocaine Solution as a Diluent to Reduce Pain After an Intramuscular Injection
- Extravasation Injury Associated Concentrated Dextrose (50% Dextrose, D50W)
- Non-Steroidal Anti-Inflammatory Drug (NSAID) Sensitivity (NSAID Intolerance)
- Allergic Contact Dermatitis Associated with a Cresol Preservative (m-Cresol, Meta-Cresol, Chlorocresol, 4-Chloro-m-Cresol)
- Allergy to Vitamin B12
- Multiple Drug Intolerance Syndrome (MDIS, Multiple Drug Allergy Syndrome, Multiple Drug Hypersensitivity Syndrome, MDHS)
- Methanol Poisoning in Moonshine and the Distillation Fractions (“Cuts”)
- Meconium, Umbilical Cord and Other Alternative Specimens for Retrospective Detection of Maternal Drug Abuse During Pregnancy
- Zinc Sulfate as an Adulterant for Urine Drug Testing
- Clinical Predictors of Lee et al for Delirium Tremens (DTs) in an Alcoholic (Early Warning Score for Delirium Tremens)
- Clinical Features of Alpha-PVP (Flakka)
- Loperamide (Imodium) Dependence and Abuse
- Adverse Effects of the Opiate Krokodil (Desomorphine)
- Clinical Features of Kratom (Mitragynine, Mitragyna speciosa) Abuse
- Methoxetamine (MXE) Intoxication and Abuse
- Different Types of Heroin
- Risk Factors for Noncompliance in the Use of Eye Drops for the Treatment of Glaucoma
- Reasons Why a Patient with Overactive Bladder (OAB) May Discontinue Therapy with an Antimuscarinic Drug
- Risk Assessment Score of Sharif-Askari et al for Predicting the Risk of an Adverse Drug Reaction (ADR) in a Hospitalized Patient with Chronic Kidney Disease (CKD)
- Leakage of Drug Following Subcutaneous or Intramuscular Injection
- Medication Wrong Route Administration Error
- Paradichloobenzene (PDB) Intoxication and Addiction (Mothball Madness)
- Use of Serum FABP1 Concentrations to Predict Outcome Associated with Acetaminophen-Induced Acute Liver Failure (ALF)
- CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Admission Model Based on Variables from King's College Criteria
- CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Admission Model Based on New Variables
- CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Post-Admission Model Based on Variables from King's College Criteria
- CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Post-Admission Model Based on New Variables
- False Positive Urine Adulterant Test for Oxidants Associated with a Urinary Tract Infection (UTI)
- Coma Cocktail
- Opiate Overdose or Sudden Death After the Loss of Tolerance During Detoxification or Imprisonment
- Carfentanil (Carfentanyl, Wildnil)
- Ultra-Potent Synthetic Cannabinoids and Zombie-Like State (AB-FUBINACA, ADB-PINACA, Other)
- Bupropion (Zyban) Abuse
- Algorithm of Kramer et al for Diagnosis of an Adverse Drug Reaction (ADR)
- Criteria of Mannesse et al for the Diagnosis of an Adverse Drug Reaction (ADR)
- Risk Factors of Mannesse et al for Hospital Admission Associated with an Adverse Drug Reaction (ADR) in an Elderly Adult
- Nonadherence Due to Pharmacophobia (Pharmaphobia, Medication Phobia)
- MARRIED-Cocaine Score for Predicting the Risk of Revisit to the Emergency Department by a Cocaine User
- Stroke or Embolic Complications of Injecting a Melted Suppository
- Vasculitis Associated with Drug Abuse
- Differential Diagnosis of Stroke and Cerebrovascular Events in a Person Who Abuses Drugs
- Lomotil (Diphenoxylate) Abuse and Dependence
- Protocol of Howes et al for Determining Adherence to Therapy for Schizophrenia
- Risk Factors of Manini et al for Adverse Cardiovascular Event (ACVE) During a Drug Overdose
- Clinical Features of 4-Aminopyridine (4-AP, Dalfampridine) Overdose
- Acute Lurasidone Overdose
- Clinical Opiate Withdrawal Scale (COWS) of Wesson and Ling
- Objective Opiate Withdrawal Scale (OOWS) of Handelsman et al
- Subjective Opiate Withdrawal Scale (SOWS) of Handelsman et al
- Alcohol Withdrawal Scale (AWS) of Wetterling et al
- Model of Palmstierna for Predicting Delirium Tremens During Alcohol Withdrawal
- Nomogram of Eyer et al for the Risk of Delirium Tremens During Alcohol Withdrawal
- Nomogram of Eyer et al for the Risk of Seizures During Alcohol Withdrawal
- Luebeck Alcohol Withdrawal Risk Scale (LARS) of Wetterling et al
- Drug Testing in a Safety-Sensitive Occupation
- Criteria for Legal Intoxication
- Criteria from Rome IV for Cannabinoid Hyperemesis Syndrome (CHS)
- Hazard Factor (HF) of Litovitz and Manoguerra
- Complications Associated with a Peripherally-Inserted Central Venous Catheter (PICC)
- Hypersensitivity Reaction to Cetuximab
- Anaphylactoid Reactions Following Parenteral Administration of Vitamin K1 (Phytonadione)
- HLA-B*58:01 Genotype and Allopurinol-Induced Hypersensitivity Reaction (Severe Cutaneous Adverse Drug Reaction, SCAR, DRESS)
- Chloroquine-Induced Renal Phospholipidosis (Pseudo Fabry Nephropathy)
- Score of Kolb and Himmelsbach for Opiate Withdrawal (Himmelsbach Scale)
- Predictors of Hedeland et al for Acetaminophen-Induced Hepatotoxicity in a Pediatric Patient
- Paracetamol Aminotransferase Product in Acetaminophen Toxicity
- Predictor of James et al for Low Risk of Acetaminophen Toxicity in a Pediatric Patient
- Mistakes in Workplace Drug and Alcohol Testing
- Short Opiate Withdrawal Score (SOWS) of Gossop
- Neonatal Withdrawal Reaction for 4-Methylcathinone
- Criteria of Alambyan for Toxic Leukoencephalopathy Associated with Heroin Inhalation ("Chasing the Dragon", CTD)
- Serum Lactate as a Predictor of Mortality in a Drug Overdose
- Coma Blisters in a Drug Overdose (Coma Bullae, Barbiturate Blisters)
- Drug Toxicity in a Nonadherent Patient
- Repeated or Recurrent Poisoning
- Adverse Drug Reactions Associated with an Overdose of a Slow or Sustained Release Drug Formulation
- Indications for Extracorporeal Therapy in Lithium Poisoning
- Indications for Extracorporeal Therapy in a Patient with Metformin Poisoning
- Indications of Ghannoum et al for Extracorporeal Therapy for Carbamazepine Poisoning
- Indications of Ghannoum et al for Extracorporeal Therapy for Theophylline Poisoning
- Indications of Ghannoum et al for Extracorporeal Therapy for Valproic Acid Poisoning
- Indications of Mactier et al for Extracorporeal Therapy for Barbiturate Poisoning
- Indications of Gosselin et al for Extracorporeal Therapy for Acetaminophen Poisoning
- Indications of Ghannoum et al for Extracorporeal Therapy for Thallium Poisoning
- Indications of Anseeuw et al for Extracorporeal Therapy for Phenytoin Poisoning
- Injection Site Reaction to Vitamin K
- Iron Intoxication from Transcutaneous Absorption
- Disseminated Intravascular Coagulopathy (DIC) and Waterhouse Friderichsen Syndrome in Colchicine Poisoning
- Diagnosis of Infection in a Patient with Colchicine Intoxication
- Cardiac Toxicity in Colchicine Poisoning
- Drug Interaction Probability Scale (DIPS) of Horn et al
- Adverse Effects of Telbivudine Therapy for Viral Hepatitis B
- Predictors of Kahn et al for Mortality in a Patient with Delirium Tremens (DTs)
- Criteria of Kahn et al for Delirium Tremens (DTs)
- Limb Amputation Associated with Intravascular Drug Abuse
- Chemsex
- Score of Camilleri for the Prediction of Acute Intoxication in a Patient with Altered Mental Status and No History of Alcohol or Drug Ingestion
- Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Administration of an Antidote
- Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Laboratory Results and Drug Combinations
- Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Drug Concentration
- Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Activation of a Resident Assessment Protocol (RAP)
- Predictors of Shively et al for a Severe Outcome in Acute Salicylate Poisoning
- Acute Hangover Scale of Rohsenow et al
- Hip Flask Defense After an Accident
- Hack Impairment Index (HII) Associated with Alcohol Intoxication
- Diphenhydramine and False-Positive Methadone Results on Urine Drug Screening
- Adverse Effects of Xylazine
- Side Effects of Cannabidiol (CBD)
- Speedball (Powerball)
- Skin Popping and Muscling
- Cannabis Concentrate (Dab, Butane Hash Oil, BHO)
- Ayahuasca
- n-Ethyl Pentylone (NEP)
- Hyperthermia Associated with a Drug of Abuse
- ICU Admission Score of Brandenburg et al for an Intoxicated/Poisoned Patient
- Factors of Al Dweik et al Affecting Patient Reporting of Adverse Drug Reactions (ADR)
- Severity Categorization for Pharmaceutical Evaluation (SCOPE) Criteria of Quintana-Barcena et al for Drug-Related Problems (DRP)
- Extravasation of Intravenous Iron
- Injection Site Reactions for Targeted and Biological Disease-Modifying Therapeutics
- Causes of a Cholinergic Crisis
- Clinical Features of a Cholinergic Crisis
- Management of a Cholinergic Crisis
- Guidance of Goldfrank et al for Intravenous Dosing of Naloxone for a Patient with Opioid Overdose
- Prediction of Alcohol Withdrawal Severity Scale (PAWSS) of Maldonodo et al
- Applejack Palsy and Hangover
- Simplified Finnegan Neonatal Abstinence Scoring Tool (FNAST) of Devlin et al
- Simplified Finnegan Neonatal Abstinence Scoring System (sFNAS) of Pomar et al
- Adverse Effects Associated with Edible Marijuana (Cannabis, THC)
- Clenbuterol Toxicity
- Clinical Features of Propylhexedrine (Benzedrex) Intoxication
- Adverse Effects of Concurrent Exposure to Cocaine and Lidocaine
- Intoxication and Addiction to Phenibut (beta-Phenyl-gamma-Aminobutyric Acid, PHB)
- Cannabis (Marijuana) Tourism
- Risk Factors for Noncompliance with Oral Iron Replacement Therapy
- Factors Impacting Adherence to Therapy with Tyrosine Kinase Inhibitors (TKI)
- Medication Possession Ratio (MPR)
- Risk Factors of Col et al for Noncompliance-Related Hospital Admission for an Elderly Patient
- Intravenous Lipid Resuscitation in Drug Overdose
- Brighton Adverse Drug Reactions Risk (BADRI) Model
- Clinical Prediction Rule of Hohl et al for Detection of a Significant Adverse Drug Effect in an Emergency Department Patient
- Pseudoallergic Infusion Reaction to Intravenous Iron
- Risk Factors for Severe Extravasation Injury in Preterm Neonates
- Stages of Montgomery et al for Infiltration and Extravasation Injury
- Complement Activation-Related Pseudoallergy (CARPA)
- Pyridine Toxicity Associated with Ceftazidime Therapy
- Clinical Findings Associated with an Overdose of an Atypical Antipsychotic
- Impact of Cirrhosis on the Metabolism of Morphine
- Causes of a False-Positive Urine Drug Test for Amphetamines
- NASCORE (Neonatal Abstinence Score) of Kocherlakota et al
- Neonatal Withdrawal Reaction Following Maternal Antipsychotic Therapy During Pregnancy
- Visceral Ischemia Associated with Methamphetamine Use
- Methamphetamine-Associated Toxic Leukoencephalopathy
- Tianeptine Abuse and Withdrawal
- Predictors of Krawczyk et al Death Following a Drug Overdose
- Bad Trip
- Adverse Drug Reaction (ADR) Severity Assessment Scale of Hartwig et al
- Adverse Drug Reaction (ADR) Preventability Assessment of Hartwig et al
- DoTS (Dosing, Timing, Susceptibility) Classification of Adverse Drug Reactions
- Risk Factors of Davies et al for Adverse Drug Reactions (ADR) on a Hospitalized Patient
- Clinical Findings Associated with Phenothiazine Overdose
- Adverse Effects of Topical Methyl Salicylate Preparations
- Lactic Acidosis in a Patient with Acetaminophen (Paracetamol) Poisoning
- Pyroglutamic Acidemia in a Patient with Acetaminophen (Paracetamol) Poisoning
- Vodka Eyeballing
- Alcohol Enema (Alcohol-Induced Colitis)
- Differential Diagnosis of Shock During Alcohol Withdrawal
- Counterfeit or Fake Ethanol
- False Positive Ethanol Concentration in an Enzymatic Assay
- Implicit Bias in Drug Testing of Pregnant Mothers and Neonates
- Shortened MOTHER Neonatal Abstinence Syndrome (sMNAS-9) of Chervoneva et al
- MOTHER Neonatal Abstinence Syndrome (MNAS)
- Risk Factors of Zhao et al for Methamphetamine Withdrawal Symptoms for a Person Who Injects Drugs (PWID)
- Intoxication with 4-Methylethcathinone (4-MEC)
- 5F-Cumyl Pegaclone (SGT-151)
- Toxicological Significance Score (TSS)
- Puffy Hand Syndrome
- Cannabis/Marijuana-Related Cardiac Arrhythmias
- Telazol (Tiletamine and Zolazepam, TZ) Toxicity
- Naloxone-Induced Pulmonary Edema
- Loperamide (Imodium) Overdose
- Diabetic Ketoacidosis and Substance Abuse
- Risk Factors for Nonadherence in an Adult with Self-Neglect
- Predictors of Lee et al for Low Adherence for Oral 5-Amnosalicylic Acid (5-ASA) in a Patient with Ulcerative Colitis
- Toxicity Associated with Intravenous Nitroglycerin
- Clinical Features of a Verapamil Overdose
- Predictors of Munoz et al for Medication-Associated Altered Mental Status in a Hospitalized Patient
- Fear of Adverse Drug Reactions
- Opioid Induced Histamine Release from Mast Cells
- Clinical Features of an Overdose with Lamotrigine
- Clinical Features of an Overdose with Hydroxychloroquine
- Clinical Features of an Overdose with Vilazodone
- Clinical Features of an Overdose with Tizanidine
- Adverse Effects of 2,4-Dinitrophenol (2,4-DNP)
- Adverse Effects of Caffeine or Other Methylxanthines Used for Weight Loss
- Adverse Effects Associated with an Overdose of the Weight Loss Product Hydroxycut
- Adverse Effects of the Herbal Weight Loss Agent Garcinia cambogia
- Ketamine Dependence and Withdrawal
- Risk Score of Minkowitz et al for Opioid-Related Adverse Drug Events (ORADE) in a Surgical Patient: Model for a Male Patient
- Risk Score of Minkowitz et al for Opioid-Related Adverse Drug Events (ORADE) in a Surgical Patient: Model for a Female Patient
- Hospital Observation Upon Reversal (HOUR) Prediction Rule for Naloxone
- Vanilla Extract Abuse
- Intoxication from Inhaling Ethanol Vapor
- False-Positive Drug Screen for Lysergic Acid Diethylamide (LSD)
- Complex Persistent Benzodiazepine Dependence (CPBD)
- Protracted Withdrawal Syndrome (Postacute Withdrawal Syndrome, PAWS)
- Marijuana-Induced Gastroparesis (THC-Induced Gastroparesis)
- Intoxication with Brorphine
- Opioid-Associated Amnestic Syndrome (Amnesia)
- Adverse Effects of Exposure to Cinnamon Oil or Powder
- Vaping THC Oil
- Skin Necrosis Associated with Injection of a Drug Containing Xylazine
- 5-APB, 5-MAPB and Other Aminoalkylbenzofuran Derivatives
- Poisoning Early Warning Score of Martin-Rodriguez et al for an Adult with Acute Poisoning
- Adverse Drug Effects in an Infant Treated for Patent Ductus Arteriosus (PDA)
- POSAMINO Criteria for Alcohol-Drug Interactions: Drugs Affected by Any Amount of Alcohol
- POSAMINO Criteria for Alcohol-Drug Interactions: Drugs Affected by Large Amounts of Alcohol
- PRODIGY Score of Khanna et al for Prediction of Opioid-Induced Respiratory Depression
- Benzodiazepine Resistant Alcohol Withdrawal (RAW) Score of Benedict et al
- Drug Testing in a Chronic Pain Patient Receiving Opioids
- Iatrogenic Withdrawal Syndrome (IWS) in an Adult in the Intensive Care Unit (ICU)
- Withdrawal Assessment Tool Version 1 (WAT-1) for Opioid or Benzodiazepine Withdrawal in a Pediatric Patient
- Heroin Transverse Myelitis (Myelopathy)
- Rhabdomyolysis Associated with Heroin Abuse
- Model of Chang et al Predictive of Nonadherence with Once-Daily Glaucoma Medications
- 12-Item Malaysia Medication Adherence Assessment Tool (MyMAAT)
- New Poisoning Mortality Score (new-PMS) of Han et al
- Neonatal Adverse Event Severity Scale (NAESS) of Salaets et al
- Defective CYP2D6 Genotype and Doxepin Poisoning
- 1,1-Dufluoroethane Inhalant Abuse
- Removal of Fentanyl on Environmental Surfaces
- Dosage Adjustments to LMW Heparin or Fondaparinux in Renal Insufficiency
- Hypersensitivity Reactions to Opioids (Histamine Release, Anaphylaxis, Anaphylactoid Reaction)
- NAlaxone CARdiac Arrest Decision Instruments (NACARDI) in Occult Opioid Overdose with Cardiac Arrest
- Fentanyl-Induced Rigid Chest Syndrome (FIRCS, Wooden Chest Syndrome)
- Kudzu (Pueraria) Herbal Remedies for Hangover and Alcohol Abuse
- Addition of a Drug By the Patient to a Urine Specimen Being Used to Screen for Therapeutic Compliance
- Norbuprenorphine to Buprenorphine Ratio in a Urine Test for Buprenorphine Use
- Detection of Heroin Use By Testing for Papaverine and Its Metabolites
- Delayed Presentation of Neonatal Withdrawal Symptoms in Neonates with Congenital Hypothyroidism
- Adverse Effects pf Eutylone or Ephylone
- Complications of Using Marijuana (or Cananbis) Wax or Hash Oil
- Definition of Edwards and Aronson for Adverse Drug Reactions (ADR)
- SCoRCH Hypersensitivity Reaction
- Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Bleeding
- Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Falls, Collapse or Syncope
- Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Delirium or Confusion
- Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Abnormal Laboratory Tests
- Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Renal Insufficiency and/or Dehydration
- Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Miscellaneous Adverse Effects
- Extravasation of Concentrated Potassium Chloride Solution
- Maximum Daily Dose of a Drug Formulation Containing Propylene Glycol
- Toxigenetic Score of Weisman et al for Methotrexate
- Adverse Effects of Melatonin, Including Overdosage
- Rupture of the Urinary Bladder from Binge Drinking
- Alcohol Intolerance Syndromes Associated with Neoplastic Diseases
- Prediction Model of Simpson et al for Positive Neonatal Meconium and Urine Drug Tests
- Neonatal Gabapentin Withdrawal Syndrome
- Predictors of Mohan et al for Intensive Care for a Patient with Alcohol Withdrawal
- Post-Acute Withdrawal Syndrome (Protracted Alcohol or Drug Withdrawal)
- Predictors of Marchand et al for Alcohol Withdrawal Syndrome on Admission to a Trauma Center
- Risk Factors of Coleman et al for a Patient Leaving Against Medical Advice (AMA) During Alcohol Withdrawal
- Phenibut Withdrawal
- Precipitated Opioid Withdrawal
- Dexmedetomidine Withdrawal
- Differential Diagnosis of Impaired Vision Associated with Methamphetamine Abuse
- Predictors of Cohen et al for Opioid Overdose in a Pediatric Patient
- Methamphetamine-Induced Encephalopathy
- Clinical Features of Fenethylline (Captagon) Intoxication
- Scopolamine Poisoning Associated with Illegal Substance Abuse
- Predictors of Naim et al for Prolonged ICU Stay or Death for a Self-Poisoned Patient
- Prognostic Model of Nakafero et al for Methotrexate Toxicity in a Patient with an Immunologic Disorder
- Adverse Inpatient Medication Event Model (AIME) of Falconer et al
- PADR-EC Score of Nair et al for Predicting Hospitalization for an Adverse Drug Reaction in an Elderly Community-Dwelling Adult
- Adverse Effects Associated with Syringe Lubricant
- Cauda Equina Syndrome Due to Intrathecal Drug Injection
- Algorithm of Kim et al for Management of Computed Tomography Contrast Media Extravasation
- Implications of CYP2D6 Genotype for a Patient Receiving Tamoxifen
- CYP2D6 Activity Score of Gaedigk et al